
Fractyl Health Stock
Fractyl Health is a biotechnology company that provides curative therapies for metabolic diseases.
Sign up today and learn more about Fractyl Health Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Fractyl Health Stock
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers. Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Funding History
March 2013 | $14.3M |
---|---|
September 2014 | $19.8M |
November 2015 | $57.0M |
November 2017 | $44.0M |
August 2020 | $55.0M |
June 2021 | $100M |
January 2022 | $20.1M |
Management
Co-Founder & CEO
Harith Rajagopalan
Co-founder & President
Jay Caplan
Board Member
Brian Dovey
Chief Financial Officer
Lisa Davidson
Vice President of Quality Assurance and Regulatory Affairs
Jon Fitzgerald
Board Member
Stanley Lapidus
Board Member
Amy Schulman
Lead Investor
Hemant Taneja
Chief Medical Officer
Juan Carlos Lopez-Talavera
Board Member
William W. Bradley
Board Member
Michael Huang
Chief Commercial Officer
Margaret Borys
Member Board of Directors
Stanley Lapidus
Vice President of Manufacturing
Len Rosberg
Board Member
John Amatruda
Board Chairman
Allan Will
Board Member
Harith Rajagopalan
Board Member
Chris Gabrieli
Board Member
Ajay Gopal Royan
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase